Treatment of Hepatitis C in the Patient with Decompensated Cirrhosis

Everson, Gregory T.; Bhatt, Asmeen

doi:10.1007/s11901-013-0181-7

Cited by 2 publications

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interferon-based therapy was the only treatment option for HCV prior to the DAA era, however, interferon was contraindicated in patients with advanced liver cirrhosis. This negatively impacted the HCV outcome in cirrhotic and organ transplant patients [63][64][65].…”

Section: Pegylated Interferon and Ribavirin (Rbv)mentioning

confidence: 99%

Liver Transplantation and HCV Genotype 4

Alghamdi¹,

Al–Hamoudi²

2021

Advances in Hepatology

View full text Add to dashboard Cite

End-stage liver disease secondary to hepatitis C virus (HCV) infection is a major indication for liver transplantation (LT) worldwide. Previous studies have shown a negative impact of HCV on patient and graft survival leading to an inferior transplant outcome when compared to other liver transplant indications. The percentage of HCV patients infected with genotype 4 (G4) among recipients of OLT varies depending on geographic location. In the Middle East HCV-G4 infection is the most common genotype among transplant recipients. Direct antiviral agents (DAAs) have revolutionized the management of HCV infection in the pre- and post-transplant setting. Recent clinical trials have shown high sustained virologic response rates, shorter durations of treatment, and decreased adverse events when compared with the previous treatment of pegylated interferon (PEG-IFN)-based therapy. However, most of these studies were performed in HCV-G1-infected patients. Due to the low prevalence of HCV-G4 in Europe and the USA, this genotype has not been adequately studied in prospective trials evaluating treatment outcomes. The aim of this chapter is to summarize the natural history and treatment outcome of HCV-G4 in the liver transplant setting, with particular attention to new HCV therapies.

show abstract

Section: Pegylated Interferon and Ribavirin (Rbv)mentioning

confidence: 99%